May 04, 2026 FDA Expands ASCENIV Pediatric Use Label change follows completion of required pediatric evaluation and updates prior age restrictions for treatment eligibility. Conexiant
May 04, 2026 Zoldonrasib in Patients With KRAS G12D–Mutant NSCLC Previously Treated With Chemoimmunotherapy The ASCO Post
May 04, 2026 Zoldonrasib in Patients With KRAS G12D–Mutant NSCLC Previously Treated With Chemoimmunotherapy The ASCO Post
May 04, 2026 Zoldonrasib in Patients With KRAS G12D–Mutant NSCLC Previously Treated With Chemoimmunotherapy The ASCO Post
April 20, 2026 Elisrasib Demonstrates High Disease Control Rate in KRAS G12C–Mutant NSCLC The ASCO Post